Fig. 1 · Structure

Documents & Downloads

Y-27632 2HCl

Cat. No. A11001 CAS 129830-38-2

ROCK Inhibitor

Also available in: DFICBY Astrocyte-to-Neuron Reprogramming Kit

Y-27632 is a Rho-Associated Coil Kinase (ROCK) inhibitor that increases the cloning efficiency of human embryonic stem cells (hESCs).

In Stock

Publications for Y-27632 2HCl

61 publications citing this product

  1. Yiming Peng-Winkler, .et al. , Nature, 2026, Jul 1 PMID: 42386979
  2. Yuan Liang, .et al. , Stem Cell Res, 2026, Aug:94:104019 PMID: 42248116
  3. Takanobu Hara, .et al. , Cell Transplant, 2026, Jan-Dec:35:9636897261446732 PMID: 42233182
  4. Yuan Liang, .et al. , Stem Cell Research, 2026, 94: 104010 PMID: 42105440
  5. Jin-Young Lee, .et al. , Mater Today Bio, 2026, Mar 19;38:103026 PMID: 41953717
  6. Yuan Liang, .et al. , Stem Cell Research, 2026, 93: 103965 PMID: 41864154
  7. Rahman Sabahi-Kaviani, .et al. , Micromachines (Basel), 2026, Feb 1;17(2):199 PMID: 41753855
  8. Dolma Choezom, .et al. , Small Sci, 2025, Dec 15;6(1):e202500470 PMID: 41532070
  9. Satoru Okada, .et al. , Cell Death Dis, 2025, Dec 4;16(1):885 PMID: 41339338
  10. Marcos Abreu Costa, .et al. , Genet Med, 2025, Aug 21;27(11):101562 PMID: 40852795

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
ROCK1 (p160ROCK) (Cell-free assay) Ki 140 nM
ROCK2 (Cell-free assay) Ki 300 nM

In Vitro Studies

In human periodontal ligament stem cells, Y-27632 increased EdU incorporation after 24 h exposure. This DNA-synthesis response does not establish a general survival benefit. [1]

Y-27632 did not significantly reduce serum-starvation apoptosis in the same cell type at 10 or 20 μM over 48 h. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

DNA synthesis in human periodontal ligament stem cells

Cell-based study · Cultured human periodontal ligament stem cells isolated from healthy extracted teeth [1]

Y-27632 increased EdU incorporation versus untreated cells. This endpoint indicates DNA synthesis and does not establish apoptosis protection or preserved differentiation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
EdU-positive nuclei as percentage of DAPI-positive nuclei, ordered by Y-27632 concentrationEdU incorporation 0 μM: 33.73 ± 2.06%; 5 μM: 44.70 ± 3.53%; 10 μM: 50.3 ± 2.42%; 20 μM: 49.55 ± 2.43%; 40 μM: 43.85 ± 2.37% (mean ± SEM)[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 5, 10, 20 or 40 μM
Exposure duration
24 h treatment; 2 h EdU labeling
Method
Addition to DMEM containing 10% FBS
Co-treatment
No additional experimental drug
Reported limits
Stock solvent not specified in the read assay methods. Methods describe five separate EdU experiments; the final Figure 1 caption n = 3 statement follows the colony panel, so a single definitive EdU n is not assigned.
Methods and source locations

Compound reported in the paper: Y-27632; Compound label in the paper: Y-27632 dihydrochloride

Evidence for the named dihydrochloride in cultured human PDLSCs; no Adooq lot-specific validation.

Materials and methods: Cell proliferation assay; Results: Y-27632 enhanced the proliferation of PDLSCs; Figure 1B–C and caption

EdU-positive nuclei as percentage of DAPI-positive nuclei, ordered by Y-27632 concentration: EdU labeling after 24 h Y-27632 exposure in DMEM with 10% FBS; 2 h labeling. Figure 1B–C; source text supplies exact values. All treated groups exceeded untreated control; 10/20 μM comparisons P < 0.001. No exact values estimated from bars. — Materials and methods: Cell proliferation assay; Results: Y-27632 enhanced the proliferation of PDLSCs; Figure 1B–C and caption

No detected protection against serum-starvation apoptosis

Cell-based study · Cultured human periodontal ligament stem cells after 24 h serum starvation [1]

At 10 or 20 μM, Y-27632 did not significantly reduce apoptosis relative to serum-free control; the 10% FBS positive control showed lower apoptosis.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Early plus late apoptosis after serum starvation and treatmentAnnexin V/PI apoptosis 10% FBS control: 3.55 ± 0.11%; serum-free control: 8.91 ± 0.8%; 10 μM: 8.42 ± 0.13%; 20 μM: 10.05 ± 0.19% (mean ± SEM; three independent experiments)[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 10 or 20 μM
Exposure duration
48 h after 24 h serum starvation
Method
Culture without serum; 10% FBS positive-control group
Co-treatment
No additional experimental drug
Reported limits
Stock solvent not specified in the read assay methods.
Methods and source locations

Compound reported in the paper: Y-27632; Compound label in the paper: Y-27632 dihydrochloride

Evidence for the named dihydrochloride in cultured human PDLSCs; no Adooq lot-specific validation.

Materials and methods: Analysis of apoptosis by flow cytometry; Results: Y-27632 had no significant effect on apoptosis of PDLSCs; Figure 2 and caption

Early plus late apoptosis after serum starvation and treatment: Annexin V-FITC/propidium iodide flow cytometry. 10/20 μM versus serum-free control: P > 0.05; 10% FBS control lower than other groups, P < 0.05. Aggregate values from Results; representative quadrant plots are not aggregate means. — Materials and methods: Analysis of apoptosis by flow cytometry; Results: Y-27632 had no significant effect on apoptosis of PDLSCs; Figure 2 and caption

In Vivo Studies

In a unilateral renal ischemia/reperfusion rat model, unconjugated Y-27632 dihydrochloride monohydrate increased serum creatinine and reduced white blood cells versus vehicle at the tested 555 μg/kg intravenous dose. The paper’s targeted lysozyme conjugate is a different tested material. [2]

Unconjugated drug worsened renal-function and blood-count endpoints

Animal study · Male Wistar rats, 220–240 g, unilateral renal ischemia/reperfusion [2]

At the tested low dose, unconjugated drug increased serum creatinine and reduced white blood cells versus vehicle at day 4. Favorable targeted-conjugate results cannot be assigned to unconjugated Y-27632.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Serum creatinine at day 4 after unilateral renal ischemia/reperfusionSerum creatinine Vehicle: 24.40 ± 0.80 μmol/L; unconjugated Y27632: 27.40 ± 0.87 μmol/L (mean ± SEM; P < 0.05 versus vehicle)[2]
White blood cell count at day 4WBC count Vehicle: 12.09 ± 1.04 ×10^9/L; unconjugated Y27632: 9.13 ± 0.68 ×10^9/L (mean ± SEM; P < 0.05 versus vehicle)[2]

Conditions shared by the study groups

Route
Intravenous
Frequency
According to unilateral Methods: 2 h before ischemia, then 24, 48 and 72 h after I/R. Results describe simultaneous initiation; discrepancy unresolved.
Treatment course
Day-4 assessment, 24 h after last dose
Vehicle
5% glucose vehicle comparator
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Unconjugated Y27632
555 μg/kg per administration
I/R + 5% glucose vehicleSerum creatinine increased and WBC count decreased versus vehicle (both P < 0.05).[2]
I/R vehicle controlReference group for unconjugated drugDay-4 serum creatinine 24.40 ± 0.80 μmol/L; WBC 12.09 ± 1.04 ×10^9/L.[2]
Unconjugated Y27632
Model: Male Wistar rats, 220–240 g; unilateral renal ischemia/reperfusion
Reported limits: Table 1 distinguishes blood-count subsets for vehicle and conjugate but gives no separate free-drug endpoint n.
I/R vehicle control
Model: Male Wistar rats, 220–240 g; unilateral renal ischemia/reperfusion
Reported limits: Table 1 distinguishes blood-count subsets for vehicle and conjugate but gives no separate free-drug endpoint n.
Methods and source locations

Compound reported in the paper: Y-27632; Compound label in the paper: Unconjugated Y27632 (dihydrochloride monohydrate)

Unconjugated Y-27632 salt evidence with monohydrate explicitly reported; catalog hydration and lot equivalence unverified. Dose is reproduced without conversion.

Table 1 (serum creatinine and WBC rows; footnotes a,e); Concise Methods: Animal Experiments, Effect of Y27632-LZM in Unilateral Renal I/R Model in Rats; material identity subsection; Results: Effect of Renal-Delivered Y27632 in the I/R Model in Rats, simultaneous-initiation sentence; Concise Methods: Effect of Y27632-LZM in Unilateral Renal I/R Model in Rats, preinjection paragraph

Serum creatinine at day 4 after unilateral renal ischemia/reperfusion: Actual Table 1, creatinine row and footnotes a,e. Source Methods assign vehicle n = 12 and free-drug n = 6; Table 1 provides no separate creatinine-specific sample count. — Table 1 (serum creatinine and WBC rows; footnotes a,e); Concise Methods: Animal Experiments, Effect of Y27632-LZM in Unilateral Renal I/R Model in Rats; material identity subsection

White blood cell count at day 4: Table 1 WBC row and footnotes a,e. Vehicle WBC n = 7; free-drug cohort n = 6 in Methods, but a separate endpoint-specific free-drug n is not stated in Table 1. — Table 1 (serum creatinine and WBC rows; footnotes a,e); Concise Methods: Animal Experiments, Effect of Y27632-LZM in Unilateral Renal I/R Model in Rats; material identity subsection

Unconjugated Y27632 · Table 1 (serum creatinine and WBC rows; footnotes a,e); Concise Methods: Animal Experiments, Effect of Y27632-LZM in Unilateral Renal I/R Model in Rats; material identity subsection; Results: Effect of Renal-Delivered Y27632 in the I/R Model in Rats, simultaneous-initiation sentence; Concise Methods: Effect of Y27632-LZM in Unilateral Renal I/R Model in Rats, preinjection paragraph

I/R vehicle control · Table 1 (serum creatinine and WBC rows; footnotes a,e); Concise Methods: Animal Experiments, Effect of Y27632-LZM in Unilateral Renal I/R Model in Rats; material identity subsection; Results: Effect of Renal-Delivered Y27632 in the I/R Model in Rats, simultaneous-initiation sentence; Concise Methods: Effect of Y27632-LZM in Unilateral Renal I/R Model in Rats, preinjection paragraph

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 129830-38-2
Applications ROCK Inhibitor
Formula C14H21N3O.2HCl
Molecular Weight 320.3
SMILES
C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1.Cl.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 61 mg/mL (190.46 mM)
Water 13 mg/mL (40.59 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
saline

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Wang T, Kang W, Du L, et al. Rho-kinase inhibitor Y-27632 facilitates the proliferation, migration and pluripotency of human periodontal ligament stem cells Journal of Cellular and Molecular Medicine (2017). PMID: 28661039 DOI: 10.1111/jcmm.13222 Source material
  2. [2] Prakash J, de Borst MH, Lacombe M, et al. Inhibition of Renal Rho Kinase Attenuates Ischemia/Reperfusion-Induced Injury Journal of the American Society of Nephrology (2008). PMID: 18650485 DOI: 10.1681/ASN.2007070794 Source material

Publications

61 publications citing this product

  1. Yiming Peng-Winkler, .et al. , Nature, 2026, Jul 1 PMID: 42386979
  2. Yuan Liang, .et al. , Stem Cell Res, 2026, Aug:94:104019 PMID: 42248116
  3. Takanobu Hara, .et al. , Cell Transplant, 2026, Jan-Dec:35:9636897261446732 PMID: 42233182
  4. Yuan Liang, .et al. , Stem Cell Research, 2026, 94: 104010 PMID: 42105440
  5. Jin-Young Lee, .et al. , Mater Today Bio, 2026, Mar 19;38:103026 PMID: 41953717
  6. Yuan Liang, .et al. , Stem Cell Research, 2026, 93: 103965 PMID: 41864154
  7. Rahman Sabahi-Kaviani, .et al. , Micromachines (Basel), 2026, Feb 1;17(2):199 PMID: 41753855
  8. Dolma Choezom, .et al. , Small Sci, 2025, Dec 15;6(1):e202500470 PMID: 41532070
  9. Satoru Okada, .et al. , Cell Death Dis, 2025, Dec 4;16(1):885 PMID: 41339338
  10. Marcos Abreu Costa, .et al. , Genet Med, 2025, Aug 21;27(11):101562 PMID: 40852795
  11. Miguel L Agoncillo, .et al. , Eur J Pharmacol, 2025, Jun 15:997:177465 PMID: 40054721
  12. Peilin Li, .et al. , Ecotoxicol Environ Saf, 2024, Dec:288:117330 PMID: 39571255
  13. Takaaki Fujimura, .et al. , NPJ Precis Oncol, 2024, Nov 17;8(1):264 PMID: 39551860
  14. Ayumi Horikawa, .et al. , In Vitro Cell Dev Biol Anim, 2024, Nov 15 PMID: 39546193
  15. Giovanni Tosi, .et al. , Nat Commun, 2024, Sep 18;15(1):8214 PMID: 39294175
  16. Christina Zarouchlioti, .et al. , EBioMedicine, 2024, Oct:108:105328 PMID: 39278108
  17. Kyunghyun Park, .et al. , Advanced Therapeutics, 2024, 7(6)
  18. Maude Hamilton, .et al. , Biol Open, 2024, Jan 15; 13(1): bio059919 PMID: 38252116
  19. Oliver Podmanicky, .et al. , Hum Mol Genet, 2024, Mar 1; 33(5): 435-447 PMID: 37975900
  20. Masayuki Fukumoto, .et al. , PLoS One, 2024, Dec 5;19(12):e0313312 PMID: 39636897
  21. Johannes Robert Fleischer, .et al. , Mol Cancer, 2023, Jan 24;22(1):17 PMID: 36691028
  22. Vignesh Jayarajan, .et al. , Cells, 2023, Jan 17;12(3):346 PMID: 36766688
  23. Giulia Bastianello, .et al. , Cell Rep, 2023, Dec 26;42(12):113555 PMID: 38088930
  24. Charlotte Phelps, .et al. , Sci Rep, 2023, Oct 23;13(1):18062 PMID: 37872186
  25. Mathilde Meyenberg, .et al. , Sci Rep, 2023, Aug 26;13(1):13964 PMID: 37633982
  26. Yu-Ting Wu, .et al. , J Biomed Sci, 2023, Aug 21;30(1):70 PMID: 37605213
  27. Heming Ning, .et al. , In Vitro Cell Dev Biol Anim, 2023, Jun;59(6):410-419 PMID: 37405627
  28. Eric Lian, .et al. , STAR Protoc, 2023, May 22;4(2):102314 PMID: 37220001
  29. Stephanie T Pohl, .et al. , Methods Mol Biol, 2023, 2584:371-387 PMID: 36495461
  30. Charlotte Phelps, .et al. , Am J Physiol Cell Physiol, 2023, Mar 1;324(3):C787-C797 PMID: 36689673
  31. Shunsuke Murakami, .et al. , Regen Ther, 2022, Nov 25;21:574-583 PMID: 36475025
  32. Sergio Pedraza-Arevalo, .et al. , STAR Protoc, 2022, Aug 30;3(3):101656 PMID: 36092820
  33. Ji-Hyun Lee, .et al. , Cell Stem Cell, 2022, May 5; 29(5): 826-839 PMID: 35523142
  34. Adam Pietrobon, .et al. , Cell Rep, 2022, Jul 5;40(1):111048 PMID: 35793620
  35. Sarkawt Hamad, .et al. , Stem Cell Res Ther, 2022, Jun 11;13(1):251 PMID: 35690874
  36. Stasia Krishtul, .et al. , Polym Adv Technol, 2022, 33( 11): 3842-3852
  37. Peter T Ruane, .et al. , Hum Reprod, 2022, Apr 1;37(4):777-792 PMID: 35079788
  38. Takayuki Miyoshi, .et al. , J Gastroenterol, 2022, Jun;57(6):441-452 PMID: 35294680
  39. Ana-Maria Cujba, .et al. , Cell Rep, 2022, Mar 1;38(9):110425 PMID: 35235779
  40. Dan Zhao, .et al. , Poult Sci, 2022, Mar; 101(3): 101642 PMID: 35016046
  41. Antigoni Gogolou, .et al. , Curr Protoc, 2021, Jun;1(6):e137 PMID: 34102038
  42. Tiago De Oliveira, .et al. , Cancers (Basel), 2021, Mar 2;S2451-9456(21)00095-7 PMID: 33671096
  43. Denise Muller, .et al. , BMC Med, 2021, Nov 16;19(1):300 PMID: 34781947
  44. Ayumi Horikawa, .et al. , PloS one, 2021, Jul 12;16(7):e0254373 PMID: 34252142
  45. Hayato Mizuta, .et al. , Nat Commun, 2021, Feb 24;12(1):1261 PMID: 33627640
  46. Scott Bell, .et al. , Stem Cell Reports, 2021, Jul 13;16(7):1749-1762 PMID: 34214487
  47. Shenyang Li, .et al. , J Cell Mol Med, 2020, Dec 20;25(2):1207-1220 PMID: 33342057
  48. Takao FUCHIGAMI, .et al. , J Appl Oral Sci, 2020, 28: e20190558 PMID: 32348439
  49. Jing-Yu Lin, .et al. , Cell Discov, 2020, 6: 20 PMID: 32284878
  50. Yu Huang, .et al. , Stem Cells Int, 2019, 2019: 3975689 PMID: 31565060
  51. XinYan, .et al. , Stem Cell Res, 2019, May 17 PMID: 31141763
  52. Daniela F. Duarte Campos, .et al. , J Biomed Mater Res A, 2019, April 22 PMID: 31012205
  53. Scott Bell, .et al. , Am J Hum Genet, 2019, May 2;104(5):815-834 PMID: 31031012
  54. Ooi J, .et al. , Cell Rep, 2019, Feb 26;26(9):2494-2508 PMID: 30811996
  55. Scott Bell, .et al. , Stem Cell Reports, 2018, Jul 10; 11(1):183-196 PMID: 29937144
  56. Christina Zarouchlioti, .et al. , Am J Hum Genet, 2018, Apr 5; 102(4): 528-539 PMID: 29526280
  57. Ai Takemoto, .et al. , Sci Rep, 2017, 7: 42186 PMID: 28176852
  58. Scott Bell, .et al. , Stem Cells Transl Med, 2017, Mar; 6(3): 886-896 PMID: 28170165
  59. Ryan Lingerak, .et al. , British Journal of Cancer Research, 2025, 8(1): 756-774
  60. Sara B Linker, .et al. , Curr Biol, 2022, Nov 21;32(22):4797-4807 PMID: 36228612
  61. Renata Santos, .et al. , STAR Protoc, 2022, Mar 17;3(2):101261 PMID: 35313707

Showing 10 of 61 publications

Added to your cart

View Cart Checkout
Loading...